|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
|
US8303955B2
(en)
*
|
2005-05-26 |
2012-11-06 |
Seattle Genetics, Inc. |
Humanized anti-CD40 antibodies and their methods of use
|
|
US20090304687A1
(en)
*
|
2005-12-09 |
2009-12-10 |
Seattle Genetics , Inc. |
Methods of using cd40 binding agents
|
|
EP2125893A2
(en)
*
|
2007-01-23 |
2009-12-02 |
Xencor, Inc. |
Optimized cd40 antibodies and methods of using the same
|
|
CN101910414B
(zh)
|
2007-11-07 |
2016-01-13 |
健泰科生物技术公司 |
用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法和组合物
|
|
FR2942799B1
(fr)
*
|
2009-03-06 |
2011-02-25 |
Lfb Biotechnologies |
Anticorps monoclonal anti-rhesus d
|
|
DK2406289T3
(en)
|
2009-03-10 |
2017-05-01 |
Baylor Res Inst |
ANTIGEN PRESENTING CELL TARGETED ANTIVIRUS VACCINES
|
|
AU2010222942B2
(en)
|
2009-03-10 |
2013-01-10 |
Baylor Research Institute |
Anti-CD40 antibodies and uses thereof
|
|
CN102770457A
(zh)
|
2009-03-10 |
2012-11-07 |
贝勒研究院 |
靶向抗原呈递细胞的疫苗
|
|
CN102459639A
(zh)
|
2009-04-18 |
2012-05-16 |
健泰科生物技术公司 |
用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法
|
|
US20130052194A1
(en)
|
2009-12-16 |
2013-02-28 |
The Trustees Of The University Of Pennsylvania |
Anti-prostate cancer antibodies and methods of detection and treatment of prostate cancer using the same
|
|
HUE049849T2
(hu)
|
2010-03-31 |
2020-10-28 |
Boehringer Ingelheim Int |
Anti-CD40 antitestek
|
|
TR201909840T4
(tr)
|
2011-03-11 |
2019-07-22 |
Beth Israel Deaconess Medical Ct Inc |
Anti-CD40 antikorları ve kullanımları.
|
|
CA2831294A1
(en)
|
2011-03-25 |
2012-10-04 |
Baylor Research Institute |
Compositions and methods to immunize against hepatitis c virus
|
|
ES2709654T3
(es)
|
2011-04-29 |
2019-04-17 |
Apexigen Inc |
Anticuerpos anti-CD40 y métodos de uso
|
|
GB201115280D0
(en)
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
|
EP3753567A1
(en)
*
|
2011-10-11 |
2020-12-23 |
Viela Bio, Inc. |
Cd40l-specific tn3-derived scaffolds and methods of use thereof
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
KR102270618B1
(ko)
*
|
2012-10-30 |
2021-06-30 |
아펙시젠, 인코포레이티드 |
항-cd40 항체 및 사용 방법
|
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
|
CN120939216A
(zh)
|
2014-01-13 |
2025-11-14 |
贝勒研究院 |
抗hpv和hpv相关的疾病的新疫苗
|
|
KR102526945B1
(ko)
*
|
2014-04-30 |
2023-04-27 |
막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 |
Ｃｄ269에 대한 인간화 항체
|
|
CA2957146A1
(en)
|
2014-08-12 |
2016-02-18 |
Alligator Bioscience Ab |
Combination therapies with anti cd40 antibodies
|
|
BR112017008959A2
(pt)
*
|
2014-10-29 |
2018-01-16 |
Seattle Genetics, Inc. |
método para tratamento de uma doença.
|
|
EP3221358B1
(en)
*
|
2014-11-18 |
2021-07-21 |
Janssen Pharmaceutica, N.V. |
Cd47 antibodies, methods, and uses
|
|
AU2016249981B2
(en)
|
2015-04-13 |
2022-02-17 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer
|
|
CN107922501A
(zh)
*
|
2015-09-01 |
2018-04-17 |
勃林格殷格翰国际有限公司 |
抗cd40抗体用于治疗狼疮性肾炎的用途
|
|
BR112018004296B1
(pt)
|
2015-09-04 |
2020-05-05 |
Primatope Therapeutics Inc |
anticorpos anti-cd40 humanizados e usos dos mesmos
|
|
BR112018006251A2
(pt)
|
2015-09-30 |
2018-10-16 |
Janssen Biotech Inc |
anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
|
|
US20170101471A1
(en)
*
|
2015-10-08 |
2017-04-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Blockade of tim-1 for treating graft-versus-host disease
|
|
PE20181326A1
(es)
|
2015-11-03 |
2018-08-20 |
Janssen Biotech Inc |
Anticuerpos que se unen especificamente a pd-1 y sus usos
|
|
EA039944B1
(ru)
*
|
2016-01-27 |
2022-03-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Применение антител к cd40 для лечения волчаночного нефрита
|
|
WO2017197045A1
(en)
|
2016-05-11 |
2017-11-16 |
Movassaghi Mohammad |
Convergent and enantioselective total synthesis of communesin analogs
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
WO2018031400A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
|
WO2018031258A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
|
CN109790220A
(zh)
|
2016-08-25 |
2019-05-21 |
豪夫迈·罗氏有限公司 |
与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
|
|
WO2018071345A1
(en)
*
|
2016-10-11 |
2018-04-19 |
Integrated Biotherapeutics, Inc. |
Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop
|
|
CA3041533A1
(en)
*
|
2016-11-07 |
2018-05-11 |
Seattle Genetics, Inc. |
Distribution of engineered-cysteine caps
|
|
CN110546164B
(zh)
*
|
2016-11-11 |
2023-10-20 |
锦湖Ht株式会社 |
特异性结合cd40的抗体及其用途
|
|
CN110072553B
(zh)
|
2016-12-22 |
2023-09-15 |
豪夫迈·罗氏有限公司 |
在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
|
|
JP6997209B2
(ja)
|
2017-04-04 |
2022-02-04 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｃｄ４０およびｆａｐに特異的に結合することができる新規な二重特異性抗原結合分子
|
|
AU2018278051A1
(en)
|
2017-06-01 |
2020-01-30 |
Jiangsu Hengrui Medicine Co., Ltd. |
Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
|
|
US10610585B2
(en)
|
2017-09-26 |
2020-04-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating and preventing HIV
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
MY205342A
(en)
|
2017-11-01 |
2024-10-16 |
Hoffmann La Roche |
Bispecific 2+1 contorsbodies
|
|
CN111788227B
(zh)
*
|
2017-12-27 |
2025-02-25 |
百时美施贵宝公司 |
抗cd40抗体及其用途
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
KR20210035805A
(ko)
|
2018-06-15 |
2021-04-01 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
|
|
JP2021534196A
(ja)
|
2018-08-23 |
2021-12-09 |
シージェン インコーポレイテッド |
抗ｔｉｇｉｔ抗体
|
|
WO2020070041A1
(en)
*
|
2018-10-01 |
2020-04-09 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising anti-fap clone 212
|
|
CN112654641A
(zh)
*
|
2018-10-01 |
2021-04-13 |
豪夫迈·罗氏有限公司 |
具有与cd40的三价结合的双特异性抗原结合分子
|
|
EP3860653A1
(en)
|
2018-10-05 |
2021-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and systems for controlling the agonistic properties of antibody variable domains by light
|
|
BR112021009835A2
(pt)
|
2018-11-30 |
2021-08-17 |
Jiangsu Hengrui Medicine Co., Ltd. |
anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
|
|
US20240254248A1
(en)
|
2018-11-30 |
2024-08-01 |
Jiangsu Hengrui Medicine Co., Ltd. |
Cd40 antibody pharmaceutical composition and use thereof
|
|
WO2020227159A2
(en)
|
2019-05-03 |
2020-11-12 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity
|
|
WO2020253722A1
(en)
*
|
2019-06-17 |
2020-12-24 |
Eucure (Beijing) Biopharma Co., Ltd |
Anti-cd40 antibodies and uses thereof
|
|
EP4027998A1
(en)
|
2019-09-09 |
2022-07-20 |
Basilea Pharmaceutica International AG |
Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
|
|
US20230114107A1
(en)
|
2019-12-17 |
2023-04-13 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
TWI851885B
(zh)
*
|
2020-03-30 |
2024-08-11 |
大陸商正大天晴藥業集團股份有限公司 |
結合cd40的抗體及其用途
|
|
TW202206100A
(zh)
|
2020-04-27 |
2022-02-16 |
美商西健公司 |
癌症之治療
|
|
US20230355804A1
(en)
|
2020-06-29 |
2023-11-09 |
Flagship Pioneering Innovations V, Inc. |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
|
WO2022072523A1
(en)
|
2020-09-30 |
2022-04-07 |
Seagen Inc. |
Uveal melanoma treatment using sea-cd40
|
|
WO2022098972A1
(en)
|
2020-11-08 |
2022-05-12 |
Seagen Inc. |
Combination-therapy antibody drug conjugate with immune cell inhibitor
|
|
EP4313109A1
(en)
|
2021-03-31 |
2024-02-07 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
|
WO2022251311A1
(en)
|
2021-05-25 |
2022-12-01 |
Seagen Inc. |
Methods of quantifying anti-cd40 antibodies
|
|
CN115403670B
(zh)
|
2021-05-26 |
2026-03-10 |
安徽瀚海博兴生物技术有限公司 |
抗cd40抗体及其用途
|
|
AU2022303363A1
(en)
|
2021-06-29 |
2024-01-18 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
|
EP4377348A1
(en)
|
2021-07-30 |
2024-06-05 |
Seagen Inc. |
Treatment for cancer
|
|
US12234294B2
(en)
|
2021-11-05 |
2025-02-25 |
Kiniksa Pharmaceuticals, Gmbh |
Pharmaceutical composition of a humanized anti-CD40 antibody
|
|
US20250249278A1
(en)
|
2022-04-14 |
2025-08-07 |
Institut National de la Santé et de la Recherche Médicale |
Methods for controlling the tumor cell killing by light
|
|
US20240174732A1
(en)
|
2022-10-05 |
2024-05-30 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024191807A1
(en)
|
2023-03-10 |
2024-09-19 |
Seagen Inc. |
Methods of treating cancer with anti-tigit antibodies
|